Synergistic Microbicidal Effect of Auranofin and Antibiotics Against Planktonic and Biofilm-Encased and .

Pengfei She, Linying Zhou, Shijia Li, Yiqing Liu, Lanlan Xu, Lihua Chen, Zhen Luo, Yong Wu
Author Information
  1. Pengfei She: Department of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, China.
  2. Linying Zhou: Department of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, China.
  3. Shijia Li: Department of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, China.
  4. Yiqing Liu: Department of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, China.
  5. Lanlan Xu: Department of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, China.
  6. Lihua Chen: Department of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, China.
  7. Zhen Luo: Department of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, China.
  8. Yong Wu: Department of Clinical Laboratory, The Third Xiangya Hospital of Central South University, Changsha, China.

Abstract

Methicillin-resistant/susceptible (MRSA/MSSA) and strains are often found in community- and hospital-acquired infections. The single use of conventional antibiotics hardly completely kills the bacterial cells of interest, especially in the form of biofilms. Thus, drug repurposing and antimicrobial combination are promising ways to solve this problem. Antimicrobial susceptibility assays against cocci in a suspension and in a biofilm mode of growth were performed with broth microdilution methods. Checkerboard assays and the cutaneous mouse infection model were used to examine the activity of auranofin and conventional antibiotics alone and in combination. In the present study, auranofin possesses potent antimicrobial activities against both planktonic cells and biofilms with minimum inhibitory concentrations ranging 0.125-0.5 mg/L. auranofin in combination with linezolid or fosfomycin showed synergistic antimicrobial activities against MSSA and MRSA both and . Similarly, auranofin also behaved synergistic effect with chloramphenicol against Additionally, auranofin improved the antibiofilm efficacy of chloramphenicol and linezolid, even on the biofilms grown on a catheter surface. Though, showed significant susceptibility to AF treatment, no synergistic antimicrobial effects were observed with antibiotics we tested. In all, the use of a combination of auranofin with linezolid, fosfomycin, and chloramphenicol can provide a synergistic microbicidal effect and , which rapidly enhances antimicrobial activity and may help prevent or delay the emergence of resistance.

Keywords

References

  1. J Clin Microbiol. 2010 Feb;48(2):628-30 [PMID: 20007403]
  2. FEMS Immunol Med Microbiol. 2010 Aug;59(3):227-38 [PMID: 20412300]
  3. Future Med Chem. 2016;8(2):117-32 [PMID: 26808006]
  4. Antimicrob Agents Chemother. 2013 Jun;57(6):2743-50 [PMID: 23571534]
  5. PLoS Pathog. 2018 Jun 21;14(6):e1007084 [PMID: 29928049]
  6. Am J Clin Dermatol. 2018 Oct;19(5):671-677 [PMID: 29882122]
  7. Appl Environ Microbiol. 2015 Mar;81(6):2226-32 [PMID: 25595767]
  8. J Chin Med Assoc. 2018 Jan;81(1):7-11 [PMID: 29042186]
  9. PLoS Biol. 2017 Nov 27;15(11):e2003981 [PMID: 29176757]
  10. BMC Complement Altern Med. 2018 May 30;18(1):169 [PMID: 29848316]
  11. Antimicrob Agents Chemother. 2012 Dec;56(12):6366-71 [PMID: 23070152]
  12. Int J Antimicrob Agents. 2019 Feb;53(2):143-151 [PMID: 30315918]
  13. J Antimicrob Chemother. 2003 Jul;52(1):1 [PMID: 12805255]
  14. Curr Med Chem. 2011;18(14):2129-45 [PMID: 21517762]
  15. J Infect Chemother. 2017 Jun;23(6):368-373 [PMID: 28343752]
  16. Eur J Clin Microbiol Infect Dis. 2011 Jan;30(1):89-95 [PMID: 20844913]
  17. Proc Natl Acad Sci U S A. 2015 Apr 7;112(14):4453-8 [PMID: 25831516]
  18. Biometals. 2014 Aug;27(4):787-91 [PMID: 24820140]
  19. PLoS Biol. 2007 Nov;5(11):e307 [PMID: 18001153]
  20. J Antimicrob Chemother. 2015 Apr;70(4):979-96 [PMID: 25583746]
  21. Curr Microbiol. 2009 Aug;59(2):118-22 [PMID: 19365686]
  22. Chemotherapy. 1982;28(1):46-53 [PMID: 7056129]
  23. Int J Antimicrob Agents. 2016 Mar;47(3):195-201 [PMID: 26895605]
  24. J Antimicrob Chemother. 2015 Sep;70(9):2608-17 [PMID: 26142477]
  25. Eur J Clin Microbiol Infect Dis. 2013 Jun;32(6):815-20 [PMID: 23354672]
  26. J Antimicrob Chemother. 2012 Feb;67(2):433-9 [PMID: 22110086]
  27. Can J Infect Dis Med Microbiol. 2008 Mar;19(2):173-84 [PMID: 19352449]
  28. Diagn Microbiol Infect Dis. 2003 Apr;45(4):287-93 [PMID: 12730001]
  29. Am Fam Physician. 2015 Sep 15;92(6):474-83 [PMID: 26371732]
  30. Clin Infect Dis. 1998 May;26(5):1179-81 [PMID: 9597249]
  31. Expert Rev Anti Infect Ther. 2014 Feb;12(2):249-64 [PMID: 24392752]
  32. Int J Antimicrob Agents. 2009 Dec;34(6):506-15 [PMID: 19828298]
  33. Infect Immun. 2015 Oct 19;84(1):90-8 [PMID: 26483410]
  34. Br J Rheumatol. 1997 Aug;36(8):870-7 [PMID: 9291856]
  35. Balkan Med J. 2017 Dec 1;34(6):546-552 [PMID: 29215338]
  36. J Biomed Biotechnol. 2012;2012:618081 [PMID: 21941436]
  37. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7280-7289 [PMID: 27671070]
  38. Antimicrob Agents Chemother. 2019 Apr 25;63(5): [PMID: 30858207]
  39. Pathog Dis. 2018 Feb 1;76(1): [PMID: 29342260]
  40. Antimicrob Agents Chemother. 2013 Feb;57(2):855-63 [PMID: 23208713]
  41. MBio. 2019 Jun 4;10(3): [PMID: 31164467]
  42. PLoS One. 2014 Dec 31;9(12):e113133 [PMID: 25551618]
  43. J Bacteriol. 2014 Jun;196(11):2012-22 [PMID: 24659768]
  44. Antimicrob Agents Chemother. 2018 May 25;62(6): [PMID: 29581117]

Word Cloud

Created with Highcharts 10.0.0auranofinantimicrobialcombinationsynergisticantibioticsbiofilmslinezolidchloramphenicoluseconventionalcellssusceptibilityassaysbiofilmmodelactivityactivitiesAuranofinfosfomycinshowedeffectMethicillin-resistant/susceptibleMRSA/MSSAstrainsoftenfoundcommunity-hospital-acquiredinfectionssinglehardlycompletelykillsbacterialinterestespeciallyformThusdrugrepurposingpromisingwayssolveproblemAntimicrobialcoccisuspensionmodegrowthperformedbrothmicrodilutionmethodsCheckerboardcutaneousmouseinfectionusedexaminealonepresentstudypossessespotentplanktonicminimuminhibitoryconcentrationsranging0125-05mg/LMSSAMRSASimilarlyalsobehavedAdditionallyimprovedantibiofilmefficacyevengrowncathetersurfaceThoughsignificantAFtreatmenteffectsobservedtestedcanprovidemicrobicidalrapidlyenhancesmayhelppreventdelayemergenceresistanceSynergisticMicrobicidalEffectAntibioticsPlanktonicBiofilm-EncasedEnterococcusfaecalisStaphylococcusaureustherapysubcutaneousabscess

Similar Articles

Cited By